Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 0.54 |
| ▸ | FNTB | P49356 | 19/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 18/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8433745 | 0.96 | FNTA (0.51) | FNTAFNTBPGGT1BKCNH2CYP11B1 | |
| SCHEMBL8095475 | 0.96 | FNTA (0.51) | FNTAFNTBPGGT1BKCNH2CYP11B1 | |
| SCHEMBL8444323 | 0.94 | KCNH2 (0.49) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL8097462 | 0.94 | KCNH2 (0.49) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL8101383 | 0.94 | FNTA (0.50) | FNTAFNTBPGGT1BKCNH2CYP11B1 | |
| SCHEMBL8435191 | 0.94 | FNTA (0.50) | FNTAFNTBPGGT1BKCNH2CYP11B1 | |
| SCHEMBL8095893 | 0.94 | FNTA (0.48) | FNTAFNTBPGGT1BKCNH2CYP11B1 | |
| SCHEMBL8534261 | 0.94 | FNTA (0.48) | FNTAFNTBPGGT1BKCNH2CYP11B1 | |
| SCHEMBL8097935 | 0.93 | FNTA (0.52) | FNTAFNTBPGGT1BKCNH2CYP11B1 | |
| SCHEMBL8426008 | 0.93 | FNTA (0.49) | FNTAFNTBPGGT1BKCNH2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 426 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | claimed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | claimed |
| EP-0862435-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-02-03 | — | — | EP | claimed |
| EP-0862435-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-09-09 | — | — | EP | claimed |
| WO-1997018813-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-05-29 | — | — | WO | claimed |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2026-01-01 | — | — | US | disclosed |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | JENNINGS BARBARA BROOKE (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4552697-A2 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| EP-3514151-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | JENNINGS BARBARA BROOKE (US) | 2022-04-14 | — | — | US | disclosed |
| CN-108289922-B | Therapeutic methods and compositions for treating non-small cell lung cancer | 友杏生技医药股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| US-6245759-B1 | PYRAZOLO(1,5-A)PYRIMIDINE DERIVATIVES; ANTICARCINOGENIC AND ANTITUMOR AGENTS; ATHEROSCLEROSIS, ANGIOGENESIS INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2001028993-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO. INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029025-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| US-6127366-A | ANTICARCINOGENIC OR ANTITUMOR AGENTS | MERCK & CO., INC. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-2000053605-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | FNTA 1583/4885FNTB 1494/4885PGGT1B 2063/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885 |
| US-20220110954-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, PKM, PDK2 | FNTA 3930/4885FNTB 2686/4885PGGT1B 4596/4885 |
| US-20260000691-A1 | COMPOUNDS, METHODS, AND TREATMENTS FOR ABNORMAL SIGNALING PATHWAYS FOR PRENATAL AND POSTNATAL DEVELOPMENT | PDK1, IP6K1, IP6K3 | FNTA 3572/4885FNTB 2992/4885PGGT1B 3876/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | FNTA 3317/4885FNTB 1753/4885PGGT1B 715/4885 |
| US-12329766-B2 | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development | PDK1, PKM, PDK2 | FNTA 3930/4885FNTB 2686/4885PGGT1B 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.